Evolution of Corrona's Business
- Corrona was created in 2001 by a group of clinical researchers to address the increasing number of questions related to safety, effectiveness, and cost associated with the use of biologics in inflammatory rheumatic diseases.
- Medical Affairs teams were the first to understand the value of the Corrona database and biostatistics and epidemiology team in supporting their objectives through data analysis publications and analytics which resonate with their real-time needs.
- As Corrona refined its safety surveillance infrastructure and processes, the company expanded its capacity to provide customized Pharmacovigilance services to support regulatory agency commitments. Corrona safety data is currently being utilized for five major therapeutic products in rheumatoid arthritis and psoriasis.
- Corrona offers consulting to Commercial teams seeking to utilize real world data to support objectives and messaging throughout the product lifecycle. These activities are supported from our patient-derived data on standardized, and customized patient outcomes. A major focus of our efforts is linking our deep clinical data with claims and other data sources.